Added to YB: 2026-02-17
Pitch date: 2026-02-13
GSK [neutral]
GSK plc
+3.31%
current return
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 86.9B
Pitch Price
GBP 21.55
Price Target
N/A
Dividend
3.33%
EV/EBITDA
7.63
P/E
15.60
EV/Sales
3.08
Sector
Pharmaceuticals
Category
value
Theodosian Capital | Stocks Update 13/2/2026 - GSK – Pipeline progress
GSK (update): RSV vaccine Arexvy submitted for China regulatory review, targeting 6M over-60s (350K annual hospitalizations). First vaccine for this cohort if approved. Regulatory decision expected 2027. Expands addressable market for portfolio. Cheap vs large cap pharma peers at 11.2x 2027 P/E, 3.4% yield.
Read full article (1 min)